Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.80 |
| ▸ | DRD1 | P21728 | 1/20 | 0.80 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.80 |
| ▸ | PDE4A | P27815 | 1/20 | 0.80 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.41 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.41 |
| ▸ | KCNMB4 | Q86W47 | 1/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.40 |
| ▸ | NECTIN4 | Q96NY8 | 4/20 | 0.40 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.39 |
| ▸ | TSLP | Q969D9 | 1/20 | 0.39 |
| ▸ | RXFP4 | Q8TDU9 | 4/20 | 0.39 |
| ▸ | RXFP3 | Q9NSD7 | 4/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | SHH | Q15465 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14274896 | 0.98 | CTSL (0.77) | CTSLDRD1PTGS1PDE4AF2 | |
| SCHEMBL8235984 | 0.98 | CTSL (0.84) | CTSLDRD1PTGS1PDE4AF2 | |
| SCHEMBL14274891 | 0.96 | CTSL (0.75) | CTSLDRD1PTGS1PDE4AF2 | |
| SCHEMBL14274890 | 0.95 | CTSL (0.74) | CTSLDRD1PTGS1PDE4AF2 | |
| SCHEMBL14274582 | 0.94 | CTSL (0.78) | CTSLDRD1PTGS1PDE4AF2 | |
| SCHEMBL14274580 | 0.94 | CTSL (0.78) | CTSLDRD1PTGS1PDE4AF2 | |
| SCHEMBL14274576 | 0.94 | CTSL (0.78) | CTSLDRD1PTGS1PDE4AF2 | |
| SCHEMBL14274613 | 0.94 | CTSL (0.73) | CTSLDRD1PTGS1PDE4AF2 | |
| SCHEMBL14300849 | 0.94 | CTSL (0.77) | CTSLDRD1PTGS1PDE4AF2 | |
| SCHEMBL14274619 | 0.94 | CTSL (0.75) | CTSLDRD1PTGS1PDE4AF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-20080051326-A1 | Antiinfective Lipopeptides | CUBIST PHARMACEUTICALS, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051326-A1 | Antiinfective Lipopeptides | VIP, NGLY1, PREP | CTSL 49/4885DRD1 3359/4885PTGS1 765/4885 |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CTSL 868/4885DRD1 3591/4885PTGS1 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.